Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME)

TYME network collaborators

Research output: Contribution to journalReview article

Abstract

Thymic epithelial tumors (TETs) are a heterogenous group of rare tumors, with a complex histopatological classification. Furthermore, the recent introduction of the first TNM staging system, that is scheduled to replace the Masaoka-Koga system, may create further difficulties in TET management, that remains challenging. Several guidelines for treatment of TETs are available and provide recommendations based mainly on non randomized trials and retrospective or limited series. Often the lack of evidence leads to formulation of indications based on expert opinions. As for other rare cancers it is crucial to create networks to coordinate the work among centres involved in treatment of these diseases in order to offer the best diagnostic and therapeutic tools. For this purpose, in 2014 a network named TYME (ThYmic MalignanciEs), was founded in Italy with the aim of improving care and research in TETs. In September 2017 a panel of multidisciplinary experts from TYME network and from other Italian centres strongly involved in TET diagnosis and treatment convened a first Italian Expert meeting together with representatives of association for patients affected by rare thoracic cancers Tu.To.R, to explore how these tumors are managed in the different centres of Italy compared to ESMO guidelines. In this paper we summarize the issues discussed during that meeting and we propose recommandations based on Masaoka Koga and the new TNM staging system.

Original languageEnglish
Pages (from-to)76-87
Number of pages12
JournalCancer Treatment Reviews
Volume71
DOIs
Publication statusPublished - Dec 1 2018

Fingerprint

Practice Management
Practice Guidelines
Neoplasms
Neoplasm Staging
Italy
Guidelines
Patient Advocacy
Expert Testimony
Thymic epithelial tumor
Thorax
Research

Keywords

  • Expert meeting
  • Masaoka-Koga
  • Thymic carcinoma
  • Thymic epithelial tumors
  • Thymoma
  • TNM

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Best practices for the management of thymic epithelial tumors : A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME). / TYME network collaborators.

In: Cancer Treatment Reviews, Vol. 71, 01.12.2018, p. 76-87.

Research output: Contribution to journalReview article

@article{1594eeddc46444dcbc48f2baf9cabf56,
title = "Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME)",
abstract = "Thymic epithelial tumors (TETs) are a heterogenous group of rare tumors, with a complex histopatological classification. Furthermore, the recent introduction of the first TNM staging system, that is scheduled to replace the Masaoka-Koga system, may create further difficulties in TET management, that remains challenging. Several guidelines for treatment of TETs are available and provide recommendations based mainly on non randomized trials and retrospective or limited series. Often the lack of evidence leads to formulation of indications based on expert opinions. As for other rare cancers it is crucial to create networks to coordinate the work among centres involved in treatment of these diseases in order to offer the best diagnostic and therapeutic tools. For this purpose, in 2014 a network named TYME (ThYmic MalignanciEs), was founded in Italy with the aim of improving care and research in TETs. In September 2017 a panel of multidisciplinary experts from TYME network and from other Italian centres strongly involved in TET diagnosis and treatment convened a first Italian Expert meeting together with representatives of association for patients affected by rare thoracic cancers Tu.To.R, to explore how these tumors are managed in the different centres of Italy compared to ESMO guidelines. In this paper we summarize the issues discussed during that meeting and we propose recommandations based on Masaoka Koga and the new TNM staging system.",
keywords = "Expert meeting, Masaoka-Koga, Thymic carcinoma, Thymic epithelial tumors, Thymoma, TNM",
author = "{TYME network collaborators} and Martina Imbimbo and Margaret Ottaviano and Milena Vitali and Alessandra Fabbri and Giovanni Leuzzi and Michele Fiore and Davide Franceschini and Giulia Pasello and Matteo Perrino and Marco Schiavon and Giancarlo Pruneri and {Dei Tos}, {Angelo Paolo} and Claudia Sangalli and Garassino, {Marina Chiara} and Rossana Berardi and Alessandra Alessi and Giuseppina Calareso and Iacopo Petrini and Marta Scorsetti and Vieri Scotti and Lorenzo Rosso and Federico Rea and Ugo Pastorino and Casali, {Paolo Giovanni} and Sara Ramella and Umberto Ricardi and Laura Abate-Daga and Valter Torri and Annalisa Trama and Giovannella Palmieri and Mirella Marino and Zucali, {Paolo Andrea}",
year = "2018",
month = "12",
day = "1",
doi = "10.1016/j.ctrv.2018.10.001",
language = "English",
volume = "71",
pages = "76--87",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Best practices for the management of thymic epithelial tumors

T2 - A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME)

AU - TYME network collaborators

AU - Imbimbo, Martina

AU - Ottaviano, Margaret

AU - Vitali, Milena

AU - Fabbri, Alessandra

AU - Leuzzi, Giovanni

AU - Fiore, Michele

AU - Franceschini, Davide

AU - Pasello, Giulia

AU - Perrino, Matteo

AU - Schiavon, Marco

AU - Pruneri, Giancarlo

AU - Dei Tos, Angelo Paolo

AU - Sangalli, Claudia

AU - Garassino, Marina Chiara

AU - Berardi, Rossana

AU - Alessi, Alessandra

AU - Calareso, Giuseppina

AU - Petrini, Iacopo

AU - Scorsetti, Marta

AU - Scotti, Vieri

AU - Rosso, Lorenzo

AU - Rea, Federico

AU - Pastorino, Ugo

AU - Casali, Paolo Giovanni

AU - Ramella, Sara

AU - Ricardi, Umberto

AU - Abate-Daga, Laura

AU - Torri, Valter

AU - Trama, Annalisa

AU - Palmieri, Giovannella

AU - Marino, Mirella

AU - Zucali, Paolo Andrea

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Thymic epithelial tumors (TETs) are a heterogenous group of rare tumors, with a complex histopatological classification. Furthermore, the recent introduction of the first TNM staging system, that is scheduled to replace the Masaoka-Koga system, may create further difficulties in TET management, that remains challenging. Several guidelines for treatment of TETs are available and provide recommendations based mainly on non randomized trials and retrospective or limited series. Often the lack of evidence leads to formulation of indications based on expert opinions. As for other rare cancers it is crucial to create networks to coordinate the work among centres involved in treatment of these diseases in order to offer the best diagnostic and therapeutic tools. For this purpose, in 2014 a network named TYME (ThYmic MalignanciEs), was founded in Italy with the aim of improving care and research in TETs. In September 2017 a panel of multidisciplinary experts from TYME network and from other Italian centres strongly involved in TET diagnosis and treatment convened a first Italian Expert meeting together with representatives of association for patients affected by rare thoracic cancers Tu.To.R, to explore how these tumors are managed in the different centres of Italy compared to ESMO guidelines. In this paper we summarize the issues discussed during that meeting and we propose recommandations based on Masaoka Koga and the new TNM staging system.

AB - Thymic epithelial tumors (TETs) are a heterogenous group of rare tumors, with a complex histopatological classification. Furthermore, the recent introduction of the first TNM staging system, that is scheduled to replace the Masaoka-Koga system, may create further difficulties in TET management, that remains challenging. Several guidelines for treatment of TETs are available and provide recommendations based mainly on non randomized trials and retrospective or limited series. Often the lack of evidence leads to formulation of indications based on expert opinions. As for other rare cancers it is crucial to create networks to coordinate the work among centres involved in treatment of these diseases in order to offer the best diagnostic and therapeutic tools. For this purpose, in 2014 a network named TYME (ThYmic MalignanciEs), was founded in Italy with the aim of improving care and research in TETs. In September 2017 a panel of multidisciplinary experts from TYME network and from other Italian centres strongly involved in TET diagnosis and treatment convened a first Italian Expert meeting together with representatives of association for patients affected by rare thoracic cancers Tu.To.R, to explore how these tumors are managed in the different centres of Italy compared to ESMO guidelines. In this paper we summarize the issues discussed during that meeting and we propose recommandations based on Masaoka Koga and the new TNM staging system.

KW - Expert meeting

KW - Masaoka-Koga

KW - Thymic carcinoma

KW - Thymic epithelial tumors

KW - Thymoma

KW - TNM

UR - http://www.scopus.com/inward/record.url?scp=85055280292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055280292&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2018.10.001

DO - 10.1016/j.ctrv.2018.10.001

M3 - Review article

C2 - 30366202

AN - SCOPUS:85055280292

VL - 71

SP - 76

EP - 87

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

ER -